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The recently reported crystal structure of bovine rhodopsin revealed a cytoplasmic helix (helix 8) in addition to the seven transmembrane
helices. This domain is roughly perpendicular to the transmembrane bundle in the presence of an interface and may be a loop-like structure in
the absence of an interface. Several studies carried out on this domain suggested that it might act as a conformational switch between the
inactive and activated states of this G-protein coupled receptor (GPCR). These results raised the question whether helix 8 may be an
important feature of other GPCRs as well. To explore this question, we determined the structure of a peptide representing the putative helix
8 domain in another receptor that belongs to the rhodopsin family of GPCRs, the human h2 adrenergic receptor (hh2AR), using two-
dimensional 1H nuclear magnetic resonance (NMR). The key results from this structural study are that the putative helix 8 domain is helical
in detergent and in DMSO while in water this region is disordered; the conformation is therefore dependent upon the environment.
Comparison of data from five GPCRs suggests that these observations may be generally important for GPCR structure and function.
D 2004 Elsevier B.V. All rights reserved.Keywords: Helix 8; h2 adrenergic receptor; NMR
High-resolution three-dimensional structural informa-
tion is available for only one G-protein coupled receptor
(hh2AR). The h2 adrenergic receptor (h2AR) belongs to the
chemoreceptor family of the class A GPCRs. h AR are(GPCR), bovine rhodopsin. The structure of rhodopsin, in
the inactive state, determined from X-ray crystallography
[1] surprisingly showed an eighth helix in addition to the
expected bundle of seven transmembrane helices. Because
several studies suggested important roles for this region in
G-protein activation [2–4], the question arises how gen-
eral this helical feature is among other GPCRs. It is now
widely reported that peptides corresponding to helices [5–
17] and turns [18–26] of membrane proteins report on the
secondary structure of the native protein with fidelity.
Therefore, to approach this question about the H8 domain
in other GPCRs of the rhodopsin family in the absence of
high-resolution structures from X-ray crystallography, we
studied the structure of a peptide corresponding to the
putative helix 8 from the human h2 adrenergic receptor0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2004.01.012
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localized in several tissue types and are activated by binding
of catecholamine ligands. The molecular mechanism of
receptor activation and the structural details of Gs coupling
with the receptor are not yet understood for this receptor.
We determined the solution structure of a peptide represent-
ing H8 of hh2AR and found it to be helical under some
conditions and disordered in water. The structure of this
domain is then examined in the context of current informa-
tion from other GPCRs.1. Materials and methods
1.1. Synthesis of peptide
The peptide representing H8 of hh2AR was chemically
synthesized at the Biotechnology center, University of
Connecticut, Storrs, CT using solid phase peptide synthesis
with Fmoc chemistry. The resulting peptide was purified on
a C18 column using reverse phase column chromatography.
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and corresponds to L324–N357 as shown:
324LIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSN357
 ðH8BARÞ
The amino acids underlined belong to the NPXXY
sequence that is conserved in the GPCR family. C341 is
the palmitoylation site.
Deuterated dodecylphosphocholine (DPC) was obtained
from Isotec (Miamisburg, OH).
1.2. Circular dichroism (CD) measurements
CD was employed to obtain information about the
secondary structure of H8BAR in DPC micelles and aque-
ous solvent. Measurements were made in a wavelength
range of 260–185 nm employing a 2-mm cuvette in a
JASCO J715 CD spectrophotometer. Samples of concentra-
tion 10 AM were used for all CD measurements. The
resulting spectra were deconvoluted to extract secondary
structure information using a neural network program,
CDNN, which utilizes a database of proteins whose second-
ary structure is already known from crystal structures [27].
However, CD of the peptide in DMSO was not obtained as
this solvent exhibits strong absorbance in the UV.
1.3. Sample preparation for nuclear magnetic resonance
(NMR) measurements of peptides
For NMR studies of H8BAR in DMSO and water,
samples were prepared by solubilizing the peptide in theFig. 1. CD spectra obtained for the peptide H8BAR in aqdeuterated solvent to a concentration of 2 mM. For detergent
micelle samples, the amount of peptide equivalent to 2 mM
was solubilized in chloroform and dried to a film. The
amount of detergent equivalent to 200 mM of deuterated
DPC was solubilized in chloroform in a separate flask and
dried to a film. The DPC film was hydrated using 9:1 water/
D2O and the resulting solution is added to the peptide film,
thus obtaining a dispersion of peptide in DPC micelles. The
pH was adjusted to about 4.0.
1.4. NMR spectroscopy
The NMR data were acquired on a Varian 600-MHz
NMR spectrometer at the University of Connecticut Health
Center, Farmington, CT. For each of the samples, a NOESY
and a TOCSY were acquired. NOESY was acquired with a
mixing time of 450 ms for the DMSO samples and mixing
times of 100 and 150 ms for micelle samples. TOCSY was
acquired with a mixing time of 70 ms in the case of both
DPC micelles and DMSO. The resulting FIDs were pro-
cessed using NMRPipe [28]. Processing was done using a
Guassian window function for the direct dimension with the
parameters lb = 16 and gc = 0.197, and a 70j shifted
squared sinebell in the indirect dimension.
1.5. Structure calculations
Sequence-specific resonance assignments were made
using the procedure described by Wu¨thrich [29]. Reso-
nance assignments were obtained using the program
FELIX (Accelrys Inc.). NOE distance constraints were
calculated as described previously [30]. Structure calcula-ueous solvent and in the presence of DPC micelles.
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simulated annealing protocol as described previously
[30]. A model peptide was built using the Biopolymer
module of the Sybyl (TRIPOS, St. Louis) package and all
the distance constraints written on it. The resulting model
was used as a starting structure for simulated annealing
calculations. The omega torsion angle was restricted to
180j throughout all the structure calculations. The starting
structure was heated to 1000 jK for 1000 fs in simulation
and cooled to 200 jK for 1500 fs in silico. Ten cycles of
simulated annealing were performed and the resulting
structures were energy minimized employing the Kollman
All Atom force field.Table 1
Table showing the proton chemical shifts for the peptide H8BAR in the
presence of the DPC micelles
Residue aH NH hH Others
Leu1 4.17 8.23 – –
Ile2 4.25 8.81 – –
Tyr3 – 8.10 – –
Cys4 – 7.99 – –
Arg5 4.16 7.87 – –
Ser6 – – – –
Pro7 – – – –
Asp8 – – – –
Phe9 – – – –
Arg10 4.44 8.11 1.80/1.89 –
Ile11 4.27 8.00 1.95 –
Ala12 4.33 8.03 1.42 –
Phe13 4.45 7.97 3.08/3.24 –
Gln14 4.33 8.28 2.22/2.38 –
Glu15 4.02 8.31 2.33/2.45 –
Leu16 – 7.88 2.01 –
Leu17 – – – –
Cys18 – – – –
Leu19 – – – –
Arg20 – – – –
Arg21 – – – –
Ser22 – – – –
Ser23 – – – –
Leu24 – – – –
Lys25 – – – –
Ala26 – – – –
Tyr27 – – – –
Gly28 4.04 8.28 – –
Asn29 – 8.31 2.90/2.95 –
Gly30 3.98/4.04 8.46 – –
Tyr31 – 8.13 3.08/3.18 –
Ser32 – 8.18 3.94/3.97 –
Ser33 – 8.34 4.01 –
Asn34 – – – –
A complete assignment of the chemical shifts was not made as TOCSY and
COSY spectra were not obtainable for this peptide in the presence of the
DPC micelles.2. Results
2.1. CD studies
Far-UV CD was employed to examine the conformation
of H8BAR in DPC micelles and aqueous solvent (CD could
not be used to study the secondary structure of H8BAR in
DMSO, as DMSO exhibits strong absorbance within the
wavelength range used). Fig. 1 shows the CD spectra for
H8BAR obtained. As can be seen in the figure, this peptide
exhibits CD that is characteristic of a helical conformation in
the presence of DPC micelles, while the peptide is disor-
dered in aqueous solvent. As calculated from the CDNN
program, H8BAR exhibits no detectable helix in the absence
of DPC whereas 31% helix is observed in the peptide in the
presence of DPC. This kind of solvent-dependent confor-
mational preference has been observed for peptides from the
H8 region of other GPCRs, for example the CB2 receptor
[31].
2.2. NMR spectra
To study the effect of solvent on the conformation of
H8BAR, we collected NMR data for the peptide in water,
DMSO, and DPC micelles. The peptide exhibited a poor
dispersion of NOESY peaks in water (data not shown),
which is characteristic of a disordered peptide in aqueous
solution. In contrast, the peptide showed a good dispersion
of NOESY peaks in DPC micelles, consistent with a well-
ordered conformation for the peptide. DPC was chosen
because it does not have a strong surface charge on the
micelle, which as discussed below may influence the
peptide structure. NMR experiments were also carried
out in DMSO. DMSO has been used as a membrane-
mimicking solvent. Structural determinations by NMR of
peptides in DMSO representing transmembrane helices of
rhodopsin [12,13,30] and bacteriorhodopsin [17] reported
with fidelity the secondary structure of the native protein
as seen in the X-ray crystal structures. Furthermore, DMSO
is not known to induce particular secondary structure and
thus is preferable to solvents like trifluoroethanol, whichstrongly stabilize a-helix. The NOESY spectrum obtained
for the peptide in DMSO showed a good dispersion of
NOESY peaks as in DPC micelles, indicating that the
peptide likely adopts a well-ordered conformation in
DMSO. These observations suggest that H8BAR adopts
a well-ordered conformation in both DPC micelles and
DMSO, whereas a disordered state is likely in aqueous
solvent. These observations are in good agreement with
those made from the CD studies. Due to the lack of
TOCSY or COSY spectra, sequence-specific resonance
assignments could not be completed for H8BAR in DPC
micelles. Assignments were obtained only for the amino
acid sequences 1–5, 10–16, and 28–33 by analyzing the
NOESY spectrum (Table 1). Therefore, a complete struc-
ture could not be determined for H8BAR in DPC micelles
using NMR. However, guided by patterns observed in the
NOESY spectrum and the CD studies, a few key features
of the structure in the presence of DPC micelles could be
obtained (see below).
et Biophysica Acta 1663 (2004) 74–81 772.3. Analysis of the low-field region of the NMR spectra
In general, a network of strong sequential NOE reso-
nances, dNN (i, i + 1) in the low-field region of the NOESY
spectrum, suggests regions of ordered structure. Fig. 2
shows the resonances that represent connectivities between
amide protons in the H8BAR. A similar pattern is observed
for the peptide in both DPC micelles and DMSO. Fig. 2 also
shows the assignment of these resonances to the respective
amino acids. The assignments indicate that the sequential
low-field NOE patterns observed correspond to regions 1–
5, 8–18 and 26–34 of the peptide in DMSO and 1–5, 10–
16 and 28–33 in DPC micelles. The observations suggest
that ordered structure would be expected in one or more of
these regions of the peptide in both DPC micelles and
DMSO.
2.4. Structure calculations
Table 2 shows proton chemical shifts for all the amino
acid residues of H8BAR in DMSO. About 310 NOE peaks
were collected from the NOESY spectrum obtained for the
peptide in DMSO. Fig. 3 shows the distribution of some of
the key NOE connectivities that are involved in folding the
peptide into its respective conformation in solution. In
particular the prevalence of ah (i, i + 3), aN (i, i+ 3), aN
(i, i + 4), NN (i, i+ 1) connectivities spanning the region S6-
M. Katragadda et al. / BiochimicaFig. 2. Spectra showing the low-field region of NOESY spectrum for the peptide
residues are represented by single letter codes and their position in the H8BAR sL16 indicates that this part of the sequence has a tendency to
adopt a helical conformation in DMSO. These 11 residues
comprise approximately 32% of the peptide in a defined
helical conformation, similar to the results from the CD with
DPC micelles. This result increases the likelihood that the
conformation of the peptide in the DPC micelles is similar
to the conformation of the peptide in DMSO. The absence
of connectivities other than sequential interactions for the
rest of the sequence precluded the determination of a well-
ordered structure for the remainder of the peptide.
Distance-restrained simulated annealing was performed
as described in Materials and methods. Fig. 4A shows the
overlay of the resulting 10 energy-minimized structures.
These structures formed a tight cluster in the region S6-C18
with a backbone RMSD of 1.2 A˚, indicating that this part of
the sequence is well defined in DMSO. Fig. 4B shows an
average structure calculated from the 10 conformers
obtained from distance-restricted simulated annealing. The
average structure is characterized by a helical conformation
starting at S6 and ending at L16.3. Discussion
A number of studies have suggested an important role for
H8 in GPCR signaling. For example, peptides of the
sequence of H8 have been shown to inhibit the signalingH8BAR in (A) DMSO and (B) in the presence of DPC micelles. All the
equence.
Table 2
Table showing the proton chemical shifts obtained for the amino acid
residues in the peptide H8BAR in DMSO
Residue aH NH hH Others
Leu1 3.93 8.17 1.55 1.63/0.91/0.94
Ile2 4.37 8.53 1.75 0.91/0.95/1.12
Tyr3 4.64 8.31 2.78, 2.98 6.70/7.09
Cys4 4.71 8.45 3.02, 3.14
Arg5 8.17 1.77, 1.58 3.16/7.62
Ser6 4.53 8.23 3.71, 3.66 5.21
Pro7 4.41 2.04, 1.91 1.84/3.71/3.75
Asp8 4.54 8.21 2.48, 2.71
Phe9 4.63 7.64 2.92
Arg10 4.34 8.36 1.81, 1.66
Ile11 4.33 7.68 1.81 1.13/0.88
Ala12 4.28 8.23 1.24
Phe13 4.48 8.05 2.96, 3.16
Gln14 4.30 8.06 1.99, 1.89 2.20/6.91/7.40
Glu15 4.36 8.13 1.96, 1.87 2.33
Leu16 4.37 8.08 1.56 0.92/0.96
Leu17 8.14 1.53 1.69/0.91/0.95
Cys18 4.67 8.30 2.99
Leu19 4.44 7.88 1.53 0.88/0.92
Arg20 4.41 8.25 1.77, 1.61 1.38/3.18/7.64
Arg21 4.27 7.88 1.77, 1.68
Ser22 4.46 8.10 3.63, 3.71 5.23
Ser23 4.41 8.14 3.68, 3.74 5.15
Leu24 4.36 8.10 0.88/0.92
Lys25 4.29 8.07 1.60, 1.72 1.38/2.84/7.74
Ala26 4.30 8.02 1.26
Tyr27 4.49 7.95 2.80, 3.00 6.73/7.10
Gly28 3.84 8.26
Asn29 4.65 8.22 2.57, 2.66 7.07/7.53
Gly30 3.70, 3.74 8.23
Tyr31 4.57 8.10 2.78, 3.04 6.73/7.13
Ser32 4.46 8.17 3.69, 3.73 5.12
Ser33 4.42 8.00 3.71 4.95
Asn34 4.61 8.20 2.57, 2.64
Fig. 4. (A) overlay of the 10 energy-minimized conformers obtained from
the simulated annealing calculations. (B) Average structure calculated from
the 10 conformers shown in A. The part of the sequence that adopts helical
conformation and designated as helix 8 (H8) is shown in red and yellow.
The labels represent the residue number in the original sequence of h2AR.
M. Katragadda et al. / Biochimica et Biophysica Acta 1663 (2004) 74–8178of rhodopsin [32], the h2AR [33], and the CB1 receptor
[34], and to activate Gi and Go proteins [35]. Therefore, H8
constitutes a region of high interest in the structure of
GPCRs (Fig. 5).Fig. 3. Connectivity plot showing the NOEs obsCD and NMR have been employed to study the con-
formational preference in different environments of H8
from hh2AR. The CD experiments and connectivity pat-
terns in the low-field region of the NOESY spectrum
obtained for H8 of hh2AR in DPC micelles show that the
sequence corresponding to H8 of hh2AR has a propensity
to adopt a helical conformation in the presence of DPC
micelles (Fig. 4A). Previous studies on analogous peptides
from adrenoreceptor from turkey erythrocytes [36], angio-
tensin II receptor [37] and CB2 receptor [31] suggested aerved for the peptide H8BAR in DMSO.
Fig. 5. Schematic representation of the sequence of h2AR. The sequence of H8 is enclosed in a box. (Figure adapted from Viseur diagram: F. Campagne and B.
Maigret, Laboratoire de Chimie The´orique de Nancy, U.A. CNRS 510 B.P. 239-54506, Vandoeuvre-les-Nancy CEDEX France and J.M. Bernassau Sanofi
Recherche, 371, Rue du Pr. Blayac, 34184 Montpellier CEDEX 4 France.)
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detergent micelles.
As complete structural details could not be obtained for
H8 of hh2AR in DPC micelles, we determined the structure
of this peptide in DMSO using NMR. The part of the
peptide (P7-L16) that is analogous to H8 in other GPCRs
studied also adopted a helical conformation in DMSO (Fig.
4B). An analogous sequence derived from cannabinoid 2
(CB2) receptor also adopted a helical conformation in
DMSO [31].
In contrast to the predominantly helical conformation
observed in the presence of DPC micelles and in DMSO,
CD and NMR studies revealed that this peptide was disor-
dered in water. These data collectively suggest that the
sequence P7-L16 in H8BAR adopts conformations depen-
dent upon environment: a helical conformation in DMSO
and in the presence of DPC micelles, and a disordered
structure in water. By comparison, H8 in rhodopsin forms a
helix as part of the whole protein in the presence of
detergent [1], while in an aqueous environment H8 of
rhodopsin does not form a helix, but rather a loop [38].
The data suggest that the conformational flexibility noted
here for H8 is a feature of both hh2AR and rhodopsin, two
GPCRs of the same family. Work on three other receptorsshows that H8 in other GPCRs follows a similar pattern.
Protein fragments of CB2 [31], the turkey adrenoreceptor
[36], and the angiotensin II AT1A receptor [37], each
corresponding to H8, also are disordered in water like
H8BAR, but ordered in a helix when bound to the surface
of a detergent micelle or in certain nonaqueous solvents.
Fig. 6 schematically summarizes the structural informa-
tion that is now known about H8 in GPCRs. Five GPCRs
have been studied in this regard. H8 from all five receptors
is non-helical in aqueous solvent. H8 from all five receptors
is helical under some specific conditions. Therefore, even
though there is little sequence homology among these five
receptors, there is structural homology. Furthermore, H8 is
conformationally flexible for all five GPCRs. This confor-
mational flexibility is likely a functionally important feature
of the receptor.
Several studies have been carried out to address the role
of helix 8 in signaling, mostly with rhodopsin. Site-directed
mutagenesis studies carried out by Altenbach et al. [2] and
Krishna et al. [3] suggested that this domain in rhodopsin
could adopt a loop-like structure when the receptor is
activated, in agreement with the structural studies summa-
rized above. Thus, the H8 domain may be acting in part as a
conformational switch between inactive and active states of
Fig. 6. Sequences of GPCR fragments, corresponding approximately to H8, for which structural information has been obtained (CB2 [31], the turkey
adrenoreceptor [36], the angiotensin II AT1A receptor [37], Hh2AR (this work) and rhodopsin [1]). The regions that have been shown to be helical in micelles
or in specific nonaqueous solvents are in the shaded boxes. In each case, these same regions are disordered in aqueous solvent (as described in the text). The
information for rhodopsin is from a different source. In the shaded box is the region in the crystal structure of the intact receptor identified as H8, obtained in
the presence of detergents. This same region is non-helical, though not disordered, in aqueous solvent, as described in the text. The tentative alignment of these
sequences is based on the NPxxY sequence, which is highly conserved in GPCRs, and is underlined for rhodopsin.
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rived from cannabinoid (CB1) receptors suggested that H8
exists in a non-helical conformation when interacting with
the G-protein [34,39], while the available data show that H8
domain is a helix in the inactive state of the receptor. Thus,
due to its conformational flexibility and implications in G-
protein activation, H8 is a critical domain of the receptor to
understand.
The question then arises: what factors may stabilize one
conformation over the other, and thus possibly influence the
activation of the receptor? The data suggest that H8 in seven
TM GPCRs is amphipathic. Fig. 7 shows a helical wheel
representation of the sequence of H8 of hh2AR in the
H8BAR sequence. As seen in the figure, one side of the
helix is defined by only hydrophobic residues while the other
side is dominated by polar residues indicating that H8 is
amphipathic. H8 of leukotriene B4 receptor is amphipathic
[4] as is H8 of rhodopsin. The amphipathic nature of H8
suggests that this domain would likely bind to the membrane
surface, possibly acting as a membrane recognition domain.Fig. 7. Helical wheel representation of H8. The line drawn across the wheel
approximately divides the hydrophobic face from the hydrophilic face.An overlay of the H8 of hh2AR on to the H8 of bovine
rhodopsin indicates that the hydrophobic face of both the
helices orient in the same direction. Thus, it can be reason-
ably assumed that H8 of hh2AR could bind to the membrane
surface similarly to H8 of rhodopsin. Beck et al. [40]
suggested that rhodopsin exhibits specific lipid binding,
which is altered upon illumination of the receptor. These
findings are supported by recent studies carried out by
Krishna et al. [3], where they showed that the secondary
structure characteristics of helix 8 depend on membrane lipid
composition, with increasing levels of phosphatidylserine
(PS) inducing helical conformation. Studies by Crain et al.
[41] showed that some of the PS cannot be labeled in rod
outer segment disk membranes possibly because PS is
protected from labeling by binding to rhodopsin. Upon
activation of the receptor, the binding between PS and H8
was shown to be altered and PS redistributed in the mem-
brane [40]. Hence, a hypothesis can be considered in which
PS binds to H8 stabilizing the helix, and the helix converts to
a loop-like conformation upon excitation of the receptor.
In addition to the membrane recognition property, the
N-terminus of H8 of bovine rhodopsin was previously
shown to be involved in initiating transducin binding
[32,42]. The involvement of the N-terminus of helix 8 in
the binding of the cognate G-protein was shown for other
receptors like rat angiotensin II receptor [35,43,44] and the
neutrophil n-formyl peptide receptor [45]. Thus, the H8
domain may act as a bifunctional structural motif in the
receptor activation.
In summary, H8 of the hh2AR can exist in two different
conformations, one a helix and the other non-helical. The
conformation is dependent upon the environment. These
data provide a reasonable framework for a model of a
conformational change in the GPCR possibly related to
receptor activation and influenced by lipid composition of
the membrane.Acknowledgements
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